Use of Car-T for lupus could drive surge in demand for a treatment that was first approved for blood cancers
Lengthy simulation of life on Mars illuminates the universal features of work, including petty irritations with colleagues
Medical historian Beth Linker provides a timely account of 20th-century America’s obsession with good posture
New Labour government seeks to rebuild global reputation after damage done by Brexit
Ariane 6 rocket must pass multiple carefully orchestrated milestones before lifting off on its first flight on Tuesday
New compound increases strength of antidote for fentanyl and other lethal drugs
New agreement hands UK drugmaker control of developing jabs and provides cash injection for German group
Luiz Amaral, CEO of the Science Based Targets initiative, cites personal reasons for exit but move follows dissent
Federal health officials step up efforts to boost jab stockpiles in response to widening outbreak
Neurotech advance gives patients in MIT study walking speed and control closer to people who had not lost limbs
Nicola Twilley explores how refrigeration turned the global food supply system into an unsustainable ‘cryosphere’
Also in this newsletter: UK growth revised upwards, France readies for election, science round-up
Information about patients remains ‘liquid gold’ when it comes to enriching medical research
Pharma group dealt another blow following decision by British to award vaccine contract to rival Pfizer
More detail and less ‘soundbites’ needed to unlock the sector’s economic potential, say science and tech groups
Delayed return of Starliner from International Space Station comes at worst possible time for US aerospace group
Discovery could allow more precise and efficient targeting of DNA modifications
Further fatalities set to follow 1,300 deaths on hajj pilgrimage, experts predict
Climate experiments rightly raise hackles but we need to find out whether these fixes could work
Oral formulation offers prospect of cheaper and more convenient access to drug, research suggests
Also in this newsletter: white hat hackers, falling birth rates, science round-up
Shares of biotech Sarepta soar 40% after approval for most expensive treatment in the world
Researchers are trying to tackle the threat before nature’s ‘flying needles’ become more prevalent and resistant to prevention
Clive Cookson selects his best mid-year reads
Critics of plan include green activists, farmers, biotech start-ups and multinationals